Physician profile
John B Sperry, JR.
NPI 1730137142
$490.09
in general payments reported to CMS, 2019-2025
10 companies · $182 in 2025
The $182 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $56.41 · 2022: $49.63 · 2023: $60.96 · 2024: $141 · 2025: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $384.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $266.24 | 2023-2025 | Qelbree, Qelbree |
| Noven Therapeutics, LLC | $41.07 | 2025 | Xelstrym |
| Glaxosmithkline, LLC. | $37.21 | 2021-2023 | Bexsero |
| Ironshore Pharmaceuticals INC. | $36.75 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $34.27 | 2023-2025 | Gardasil 9, Enflonsia, Vaxelis |
| Sobi, INC | $33.47 | 2021 | |
| Neos Therapeutics, Lp | $26.24 | 2022 | |
| Neuraxis, INC. | $14.84 | 2024 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Sperry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.